At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NAGE Niagen Bioscience
Pre-Mkt 08-03 08:17:19 EDT
3.40
+0.08
+2.41%
盘前3.42
+0.02+0.59%
08:15 EDT
High3.41Low3.21Vol648.54K
Open3.32D1 Closing3.32Amplitude6.02%
Mkt Cap271.73MTradable Cap191.57MTotal Shares79.92M
T/O2.15MT/O Rate1.15%Tradable Shares56.35M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Niagen Bioscience Inc Expected to Post Earnings of 2 Cents a Share - Earnings Preview
Reuters  ·  08-01 05:11
Niagen Bioscience Inc Expected to Post Earnings of 2 Cents a Share - Earnings Preview
Niagen Bioscience announces publication on muscle epigenetic age
TIPRANKS  ·  07-28
Niagen Bioscience announces publication on muscle epigenetic age
Niagen Bioscience Reports Analysis Finds Niagen NR Cuts Muscle Epigenetic Age by About 2.5 Years in 5-month Trial
Reuters  ·  07-28
Niagen Bioscience Reports Analysis Finds Niagen NR Cuts Muscle Epigenetic Age by About 2.5 Years in 5-month Trial
Niagen Bioscience (NAGE) Gets a Buy from Roth MKM
TIPRANKS  ·  07-27
Niagen Bioscience (NAGE) Gets a Buy from Roth MKM
Niagen Bioscience CEO to Speak at Canaccord Genuity Growth Conference
Reuters  ·  07-27
Niagen Bioscience CEO to Speak at Canaccord Genuity Growth Conference
Niagen Bioscience to Announce Second Quarter Financial Results on August 4
Deep News  ·  07-21
Niagen Bioscience to Announce Second Quarter Financial Results on August 4
Niagen Bioscience Schedules Q2 Earnings Call After Market Close
Reuters  ·  07-21
Niagen Bioscience Schedules Q2 Earnings Call After Market Close
Press Release: Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Dow Jones  ·  07-21
Press Release: Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Niagen Bioscience Names Abhijit Kale Senior Director of Global External Research
Reuters  ·  07-16
Niagen Bioscience Names Abhijit Kale Senior Director of Global External Research
Niagen Bioscience Appoints Abhijit Kale, Ph.d., as Senior Director of Global External Research
THOMSON REUTERS  ·  07-16
Niagen Bioscience Appoints Abhijit Kale, Ph.d., as Senior Director of Global External Research
Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia
MT Newswires Live  ·  07-13
Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia
Niagen Rises After U.S., EU Rare Disease Designations for Drug Candidate
Reuters  ·  07-13
Niagen Rises After U.S., EU Rare Disease Designations for Drug Candidate
Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168
TIPRANKS  ·  07-13
Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (rpd) Designation and European Medicines Agency Orphan Medicinal Product Designation (ompd) for Nb4168 for the Treatment of Ataxia Telangiectasia (a-t)
THOMSON REUTERS  ·  07-13
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (rpd) Designation and European Medicines Agency Orphan Medicinal Product Designation (ompd) for Nb4168 for the Treatment of Ataxia Telangiectasia (a-t)
Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases
MT Newswires Live  ·  07-08
Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases
Niagen Bioscience launches pharmaceutical program for aging and genetic diseases
TIPRANKS  ·  07-08
Niagen Bioscience launches pharmaceutical program for aging and genetic diseases
Niagen Bioscience initiated with a Buy at Freedom Broker
TIPRANKS  ·  07-07
Niagen Bioscience initiated with a Buy at Freedom Broker
Niagen Bioscience Shareholders Back Board and Governance Measures
TIPRANKS  ·  06-30
Niagen Bioscience Shareholders Back Board and Governance Measures
Niagen Bioscience Holds Annual Shareholder Meeting, Elects Directors
Reuters  ·  06-30
Niagen Bioscience Holds Annual Shareholder Meeting, Elects Directors
Niagen Bioscience - up to $50 Mln of Common Stock May be Sold Under Sales Agreement Dated June 26, 2026 - SEC Filing
THOMSON REUTERS  ·  06-29
Niagen Bioscience - up to $50 Mln of Common Stock May be Sold Under Sales Agreement Dated June 26, 2026 - SEC Filing

Introduction

Company Name.
Niagen Bioscience
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--